Financial Data and Key Metrics Changes - The company ended Q1 2023 with cash and cash equivalents of approximately $10 million, down from $10.9 million at the end of 2022 [8] - Total operating expenses for Q1 2023 were $9.2 million, an increase from $7.8 million in Q1 2022, primarily due to increased R&D expenditures related to U.S. clinical trials [10] - Revenue for the Nu.Q Vet Cancer Test grew by 381% to $124,000, contributing to total revenue of approximately $150,000 in Q1 2023, compared to $114,000 in Q1 2022 [11] Business Line Data and Key Metrics Changes - The Nu.Q Vet Cancer Test is now available through IDEXX's reference lab network and Heska's Veterinary Diagnostics Laboratory, marking significant commercial progress [14][15] - The company is focusing on expanding the Nu.Q Vet product into the mainstream market, targeting approximately 84 million pet dogs in the U.S. [16] Market Data and Key Metrics Changes - IDEXX plans to roll out the Nu.Q Vet Cancer Test to Canada, the UK, EU, and Australia in the second half of 2023, with potential interest in Asia [41] - The SAGE partnership has facilitated access to the Asian market, with ongoing discussions with reference labs in Southeast Asia [42] Company Strategy and Development Direction - The company aims to make canine cancer screening and monitoring accessible worldwide, with a strong focus on the Nu.Q Vet and Nu.Q NETs products [20] - The company is also investing in the background of epigenetics and the development of its Nu.Q platform for human cancer diagnostics [33] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the positive reception of the Nu.Q Vet Cancer Test among veterinarians and the potential for significant revenue generation [27] - The company anticipates a gradual increase in orders for the Nu.Q Vet Cancer Test, although it may be somewhat lumpy due to the rollout schedule [28][29] Other Important Information - The company received approximately $8 million in net proceeds from a public offering in February 2023 and expects to receive an additional $13 million in milestone payments [9] - A peer-reviewed paper on the Nu.Q Vet Cancer Test was published, highlighting its utility in monitoring canine lymphoma, which could open new market opportunities [17][18] Q&A Session Summary Question: Insights into ordering patterns from vet labs - Management does not have formal data but reports positive feedback from partners regarding the utilization of the test across over 45 states [27] Question: Ordering trends and potential lumpiness - Management expects ordering trends to be somewhat lumpy as labs roll out the test at different times, with a gradual increase anticipated [28][29] Question: R&D expenditure increase - The increase in R&D expenses is primarily due to U.S. clinical trial activities focused on Nu.Q NETs, with expectations for Q2 expenditures to be lower than Q1 [31] Question: Update on Heska pre-sales - Management is unable to provide an update on Heska pre-sales at this time but anticipates being able to do so in the next quarter [36] Question: IDEXX commercialization plan outside the U.S. - IDEXX is targeting Canada, the UK, EU, and Australia for the Nu.Q Vet Cancer Test rollout, with potential interest in Japan [41] Question: Update on the SAGE partnership - The SAGE partnership has been beneficial, leading to significant interest and discussions with other reference labs in Asia [42] Question: Status of the Discover program - The Discover program is not a primary focus currently, but the company continues to pursue contracts and partnerships in this area [44]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________to_________ Commission File Number: 001-36833 VOLITIONRX LIMITED (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporat ...

© © Corporate Deck March 2023 Property of Volition 2023 Slide 1 Forward Looking Statements and Disclaimer Statements in this document may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as " ...

VolitionRx Limited (NYSE:VNRX) Q4 2022 Earnings Conference Call March 16, 2023 8:30 AM ET Company Participants Scott Powell – Executive Vice President-Investor Relations Cameron Reynolds – President and Group Chief Executive Officer Terig Hughes – Group Chief Financial Officer Tom Butera – Chief Executive Officer-Volition Veterinary Diagnostics Development LLC Conference Call Participants Bruce Jackson – Benchmark Constantine Davides – E.F. Hutton Steven Ralston – Zacks David Westenberg – Piper Sandler Jim ...

© © Corporate Deck March 2023 Property of Volition 2023 Slide 1 Forward Looking Statements and Disclaimer Statements in this document may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as " ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (State or other jurisdiction of incorporation or organization) Delaware 91-1949078 (I.R.S. Employer Identification No.) 1489 West Warm Springs Road, Suite 110 Henderson, Nevada 89014 (Address of principal executive offices) For the Fiscal Year Ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHA ...

VolitionRx Limited (NYSE:VNRX) Q3 2022 Earnings Conference Call November 15, 2022 8:30 AM ET Company Participants Scott Powell - IR Cameron Reynolds - Founder, Group CEO Tom Butera - CEO, Volition Veterinary Terig Hughes - CFO Conference Call Participants Michael Okunewitch - Maxim Group Bruce Jackson - The Benchmark Company Steven Ralston - Zacks Operator Good morning, ladies and gentlemen. Thank you for standing by. Welcome to VolitionRx Limited's Third Quarter 2022 Earnings Conference Call. [Operator Ins ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36833 VOLITIONRX LIMITED (Exact name of registrant as specified in its charter) Delaware 91-1949078 (State or other jurisdiction of incor ...

VolitionRx Limited (NYSE:VNRX) Q2 2022 Earnings Conference Call August 11, 2022 8:30 AM ET Company Participants Scott Powell - IR Cameron Reynolds - CEO Dr. Tom Butera - CEO, Volition Veterinary Terig Hughes - CFO Conference Call Participants Ross Osborn - Cantor Fitzgerald Bruce Jackson - The Benchmark Company Nathan Weinstein - Aegis Capital Steven Ralston - Zacks Operator Good morning, ladies and gentlemen, and thank you for standing by. Welcome to VolitionRx Limited's Second Quarter '22 Earnings Confere ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (I.R.S. Employer Identification No.) 1489 West Warm Springs Road, Suite 110 Henderson, Nevada 89014 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36833 VOLITIONRX LIMITED (Exact name of re ...